Tarun Rustagi, MD
Gastroenterology · San Francisco, CANPI 1801045513
Payments from drug & device makers
Across 119 payments — averaging $270.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$31K
- Cook Medical LLC$358
- AbbVie$210
- Steris Corporation$93
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$93
- Endogastric Solutions, Inc$78
- plus $298 from 8 others
What the payments were for
- Consulting fees$9,76930%
- Speaking & faculty fees$13,57542%
- Travel & lodging$4,44814%
- Food & beverage$4,41914%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 79 | $31,080 |
| Cook Medical LLC | 10 | $358 |
| AbbVie | 10 | $210 |
| Steris Corporation | 1 | $93 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $93 |
| Endogastric Solutions, Inc | 1 | $78 |
| Merit Medical Systems Inc | 3 | $64 |
| Olympus America Inc. | 1 | $55 |
| Lumendi LLC | 1 | $52 |
| Micro-tech Endoscopy USA, Inc. | 2 | $35 |
| UCB, Inc. | 2 | $34 |
| Intercept Pharmaceuticals, Inc. | 2 | $26 |
| Bristol Myers Squibb | 1 | $19 |
| Exelixis Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACQUIRE$14,361
- GENERAL - METAL STENTS - G.I.$5,092
- AXIOS$2,372
- GENERAL - THERAPIES$1,739
- GENERAL - BILIARY DEVICES$1,338
- Cook Medical Endoscopic Ultrasound$108
- EXALT Model D$107
- GENERAL ENDOCHOICE$106
How this compares
$32,211 in reported general payments places this provider in the 85th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 62 | $1,049 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 60 | $951 |
| Lubiprostone | 12 | $782 |
| Pantoprazole Sodium | 81 | $740 |
| Ondansetron Hcl | 49 | $146 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $138 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in San Francisco
- Vivek RudrapatnaSan Francisco$2M
- Bruce WangSan Francisco$1.1M
- Mandana KhaliliSan Francisco$906K
- Kendall BeckSan Francisco$743K
- Uma MahadevanSan Francisco$690K
- Peter WinkleCypress$116.7M
- Manuchehr DaraniSanta Ana$17.7M
- Jatinder PruthiLancaster$4.4M
- Long DangWestminster$4.3M
- Muhammad SheikhFresno$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.